By acting on NMDA receptors, Auvelity attempts to alter glutamate levels in the brain. Currently, available antidepressants alter neurotransmitters like serotonin and noradrenaline. According to researchers, Auvelity is the first-of-its-kind drug.
Drugs in this class, including ketamine. are referred to as glutamate modulators. This drug is a result of research on ketamine as a treatment for clinical depression. Over the past ten years, research has shown that ketamine has an immediate, potent antidepressant impact.
The use of ketamine in treatment marked a significant shift since it was the first time in many years that researchers had access to an antidepressant that operated differently from all the others.
Auvelity is a pharmaceutical that combines the effects of two different drugs. An earlier medication called dextromethorphan has some modifying properties. Bupropion, the other medication in the combination, is an effective antidepressant on its own. Bupropion’s role in this drug is to slow dextromethorphan metabolism, though.
A new therapeutic option for patients whose illness has proven resistant to other types of therapy is provided by the novel drug combination, which holds promise for the future of treating depression.